Based on the promising results obtained with pharmacological CXCR4 antagonists, several anti-CXCR4 antibodies have been produced and tested in preclinical models against different types of leukemia [208,209,210], and some of them have entered into clinical trials. This evidence concerns the gene CXCR4 and leukemia.